Structural Modification in Osteoarthritis: Dawn of a New Day?
Authors: Jeffrey N. Katz
Journal: Annals of Internal Medicine (2019)

Editorials21 January 2020Structural Modification in Osteoarthritis: Dawn of a New Day?Jeffrey N. Katz, MD, MScJeffrey N. Katz, MD, MScBrigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts (J.N.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-3809 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Osteoarthritis (OA) of the knee is a painful, disabling condition affecting more than 14 million people in the United States (1) and hundreds of millions worldwide. The pain of this condition arises from a series of pathologic processes involving articular cartilage, subchondral bone, synovium, meniscus, and other joint structures, ultimately leading to joint failure and pain-related functional limitations. Scientists around the world have worked to identify biological pathways underlying these destructive changes and to develop targeted therapies that address these pathways. These efforts have enhanced our understanding of the pathobiology of OA but have not yet succeeded in identifying a ...References1. Deshpande BR, Katz JN, Solomon DH, et al. Number of persons with symptomatic knee osteoarthritis in the US: impact of race and ethnicity, age, sex, and obesity. Arthritis Care Res (Hoboken). 2016;68:1743-50. [PMID: 27014966] doi:10.1002/acr.22897 CrossrefMedlineGoogle Scholar2. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27:1578-89. [PMID: 31278997] doi:10.1016/j.joca.2019.06.011 CrossrefMedlineGoogle Scholar3. Lindstrom E, Grabowska U, Jerling M, et al. MIV-711, a highly selective cathepsin K inhibitor, reduces biomarkers of bone resorption and cartilage degradation in healthy subjects. Osteoarthritis Cartilage. 2014;22 Suppl S197. doi:10.1016/j.joca.2014.02.376 CrossrefMedlineGoogle Scholar4. Conaghan PG, Bowes MA, Kingsbury SR, et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis. A randomized, placebo-controlled study. Ann Intern Med. 2020;172:86-95. doi:10.7326/M19-0675 LinkGoogle Scholar5. Hunter D, Nevitt M, Lynch J, et al; FNIH OA Biomarkers Consortium. Longitudinal validation of periarticular bone area and 3D shape as biomarkers for knee OA progression? Data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis. 2016;75:1607-14. [PMID: 26483253] doi:10.1136/annrheumdis-2015-207602 CrossrefMedlineGoogle Scholar6. Hochberg MC, Guermazi A, Guehring H, et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA. 2019;322:1360-70. [PMID: 31593273] doi:10.1001/jama.2019.14735 CrossrefMedlineGoogle Scholar7. Culvenor AG, Collins NJ, Guermazi A, et al. Early knee osteoarthritis is evident one year following anterior cruciate ligament reconstruction: a magnetic resonance imaging evaluation. Arthritis Rheumatol. 2015;67:946-55. [PMID: 25692959] doi:10.1002/art.39005 CrossrefMedlineGoogle Scholar8. U.S. Department of Health and Human Services; U.S. Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics. May 2014. Accessed at www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf on 9 December 2019. Google Scholar9. U.S. Department of Health and Human Services; U.S. Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research; Center for Devices and Radiological Health. Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment. Guidance for Industry. August 2018. Accessed at www.fda.gov/media/71132/download on 9 December 2019. Google Scholar Author, Article, and Disclosure InformationAffiliations: Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts (J.N.K.)Acknowledgment: The author thanks Emma E. Williams, BA, for expert editorial assistance.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3809.Corresponding Author: Jeffrey N. Katz, MD, MSc, Department of Orthopedic Surgery, Brigham and Women's Hospital, Hale 5016, 75 Francis Street, Boston, MA 02115; e-mail, [email protected]harvard.edu.This article was published at Annals.org on 31 December 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDisease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis Philip G. Conaghan , Michael A. Bowes , Sarah R. Kingsbury , Alan Brett , Gwenael Guillard , Biljana Rizoska , Niclas Sjögren , Philippa Graham , Åsa Jansson , Cecilia Wadell , Richard Bethell , and John Öhd Metrics 21 January 2020Volume 172, Issue 2Page: 147-148KeywordsAnterior cruciate ligamentArthralgiaBoneCartilageFood and Drug AdministrationKneesOsteoarthritisOsteocalcinRandomized trialsUrine ePublished: 31 December 2019 Issue Published: 21 January 2020 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...